Annexon

Annexon EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Annexon (ANNX) as of Oct 30, 2026 is -77.96 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -44.01 % — a change of 77.14% (lower).

EBIT/Assets

-77.96 %

YoY

77.14%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Annexon is 2025 -77.96 % . Operating Income to Assets Ratio (EBIT/Assets) of Annexon was 2024 -44.01 % . It decreases by 77.14% lower compared to the previous year.

The Annexon EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-39.77 USD
Jan 1, 2019
-65.17 USD
Jan 1, 2020
-17.83 USD
Jan 1, 2021
-45.54 USD
Jan 1, 2022
-51.07 USD
Jan 1, 2023
-48.28 USD
Jan 1, 2024
-44.01 USD
Jan 1, 2025
-77.96 USD
The Annexon EBIT/Assets history
YEAREBIT/AssetsYoY
-77.96 %+77.14%
-44.01 %-8.84%
-48.28 %-5.46%
-51.07 %+12.15%
-45.54 %+155.39%
-17.83 %-72.64%
-65.17 %+63.88%
-39.77 %-84.81%
-261.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Annexon Stock analysis

What does Annexon do? Annexon Inc is a biopharmaceutical company based in South San Francisco, California. It was founded in 2011 by Doug Love, Ted Love, and Arnon Rosenthal, who had previously worked at major pharmaceutical companies such as Genentech and Novartis. The company's main goal is to develop new treatment options for neurodegenerative diseases, focusing on the development of drugs that target the autophagy process in cells to reduce damage to nerve cells and alleviate symptoms. Annexon Inc has two divisions, Annexon Biosciences and Annexon Clinical, with partnerships with renowned pharmaceutical companies to advance drug development. Its main product is ANX005, a therapeutic antibody protein that targets the role of the complement system in neurodegenerative diseases. Annexon Inc has received multiple awards for its work and innovations and has a dedicated team of scientists and executives committed to improving the lives of people with neurodegenerative diseases. Annexon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Annexon stock

Operating Income to Assets Ratio (EBIT/Assets) of Annexon is -77.96 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Annexon changed from -44.01 % to -77.96 %, representing a 77.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Annexon since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Annexon with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Annexon

All Key Metrics — Annexon